Navigation Links
InterMune Appoints Angus C. Russell to Board of Directors
Date:10/31/2011

BRISBANE, Calif., Oct. 31, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Angus C. Russell, Chief Executive Officer of Shire plc, has been appointed to InterMune's Board of Directors.  Shire is a leading global biopharmaceutical company focused on meeting the needs of the specialist physician.

"Angus Russell has successfully led Shire's evolution to a leading global biopharmaceutical company with expertise in the development and commercialization of specialty medicines," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune.  "We look forward to drawing on his experience as we execute the launch of Esbriet in Europe, prepare to launch Esbriet beyond Europe and advance our other programs targeted on pulmonary and fibrotic diseases."  

Angus Russell has served as Chief Executive Officer at Shire since June 2008.  He is also the Chairman of Shire's Leadership Team and was a lead member of the Shire Management Committee that devised and implemented Shire's long-term, focused business strategy.  Prior to his current role, Mr. Russell was Chief Financial Officer at Shire from 1999 to 2008.  

Previous to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca for 19 years, most recently as Vice President of Corporate Finance at AstraZeneca PLC.  In that role he was responsible for financial input into merger and acquisition activities, management of tax, legal and finance structure, investor relations, and the management of various financial risks.  Mr. Russell also held a number of positions within Zeneca Group PLC from 1993 until 1999, including Group Treasurer.  He is a chartered accountant, having qualified with Coopers & Lybrand (now PricewaterhouseCoopers LLP).

Mr. Russell is a member of the Board of Directors of Shire and also serves as a Member of the Advisory Board of Celtic Pharma Management L.P., a private equity advisement firm.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements  

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including statements related to the commercial launch of Esbriet and InterMune's clinical development plans.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 9, 2011 and other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune to Release Third Quarter Financial Results on November 3
2. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
5. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
6. InterMune to Present at J.P. Morgan Healthcare Conference
7. InterMune Reports Third Quarter 2010 Financial Results
8. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
9. InterMune to Release Second Quarter Financial Results on July 27
10. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
11. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. ... saving and improving the lives of pets, today announced ... of the New Animal Drug Application (NADA) for Zimeta™ ... field study (KB0120) of Zimeta for the control of ... Company. --> --> ...
(Date:2/11/2016)... FRANCISCO , Feb. 11, 2016   Health ... advancement of new health technologies, announced today " 10 ... achievements in health tech over the past ten years.   ... For nearly a decade, Health 2.0 has served as ... showcased and connected with thousands of technologies, companies, innovators, ...
(Date:2/11/2016)... Feb. 11, 2016  MiMedx Group, Inc. (NASDAQ: ... amniotic membrane and other birth tissues, human skin and ... and market advanced products and therapies, announced today that ... Global Healthcare Conference in New York ... Michael J. Senken , Chief Financial Officer and ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center for ... General Hospital on April 5-7. The series is a multi-day, multi-workshop event designed ... workshops cover a broad range of topics, including coaching skills, the scientific method ...
(Date:2/12/2016)... Las Vegas, NV (PRWEB) , ... February 12, 2016 , ... ... of North Las Vegas Mayor John J. Lee, Nevada Military Support Alliance president Scott ... newest Fisher House at the VA Southern Nevada Healthcare System. This will be ...
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist Robert LaPrade, MD, ... in 2016 . The list consists of physicians establishing, leading and partnering with ambulatory ... , An Ambulatory Surgery Center, also known as an ASC, is a modern ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Donor Network West, ... California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the ... hospital’s facilities as a way to accommodate a more certain time frame for donor ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... southwest Houston and surrounding communities by continuing it’s commitment to act as Agents ... Promise. The organization works closely with area homeless families to fulfill immediate needs ...
Breaking Medicine News(10 mins):